Rheumatoid Arthritis

In phase 2 data, ABT-494 showed a significant dose response over placebo in treating rheumatoid arthritis.

A biologic agent called SB5 worked as well adalimumab,researchers reported at the American College of Rheumatology meeting in San Francisco, CA.

Anakinra shown to significantly reduce pericarditis in patients with highly inflammatory disease and elevated CRP protein.

Patient perceptions of pain and fatigue can differ from clinical markers. Knowing this can make a difference in treatment plans doctors design.

Can a person’s overall diet affect the development of rheumatoid arthritis? A new study shows that it can, especially for high-risk people.

Methotrexate is frequently prescribed incorrectly in the United States. It’s under-dosed, prescribed for inadequate time periods and is rarely switched to the subcutaneous version before biologics are initiated.

Patients with arthritis have less fatigue, greater job satisfaction, less productivity loss and less absenteeism in second-career jobs than individuals who never left the workforce due to illness.

A Swiss team found that tocilizumab (Actemra/Genentech) was effective in treating newly diagnosed or relapsed patients with giant cell arteritis.

Giant cell arteritis is effectively treated with glucocorticoids, but they have side effects and patients tend to relapse. Researchers evaluated abatacept combined with prednisone and saw fewer relapses.

Reporting at the American College of Rheumatology Annual Meeting in San Francisco, a team from Japan reported on a novel humanized monoclonal antibody called E6011, one that targets fractalkine-CX3CR1, with a research goal of stopping the chemokine's accumulation in inflamed tissues in rheumatoid arthritis.

Researchers have found several urinary biomarkers that may be used to predict rheumatoid arthritis activity and prognosis.

Compared to placebo and treatment with adalimumab, treatment with once-daily oral baricitinib was associated with significant clinical improvements in patients with rheumatoid arthritis.

The past 10 years have been marked “an explosion” of new therapies for use across the spectrum of rheumatic diseases, some with outstanding success, others, not so.

Does rheumatology research have a future in academia? Researchers say the road is littered with obstacles and challenges never before seen.

The common practice of dose-escalating TNF inhibitors to retain clinical response may not be the most cost-effective approach in rheumatoid arthritis, study shows.

A new study finds promise in the combination of toclizumab and methotrexate as a treatment for early rheumatoid arthritis.

Women with rheumatoid arthritis (RA) are at a substantially higher risk of mortality – especially those with cardiovascular and respiratory conditions.

Tocilizumab associated with left ventricular dysfunction in RA patients, correlating with a reduction in RA disease activity.

Successful clinical response to treatment with tumor necrosis factor inhibitor (TNFi) was maintained even during reduced dosages in patients with rheumatoid arthritis.

Baseline radiologic damage can predict long-term patient-related outcomes in patients with severe rheumatoid arthritis.

Severe vitamin D deficiency could be responsible for persistent rheumatoid arthritis disease activity.

When it comes to toxicology, the dose often makes the poison. Consider this report of a case of apparent mineralocorticoid excess apparently caused by licorice root extract.

Rheumatoid arthritis patients are less likely to be protected from hepatitis B than their non RA counterparts, according to research presented at the European League Against Rheumatism (EULAR) Annual Congress earlier this year in Rome, Italy.

To integrate biosimilars into clinical practice, physicians must understand variation in reference products, data, naming, labeling, interchangeability, substitution and overall drug safety.

A task force of rheumatologists, radiologists and patients has developed nine points to consider in the clinical management of juvenile idiopathic arthritis.

Rheumatoid arthritis patients on tumor necrosis factor inhibitors can safely taper or discontinue methotrexate.

Patients with early rheumatoid arthritis may have reduced myocardial and vascular function.

Rheumatology Network examines common comorbidities in rheumatoid arthritis and their role in limiting mobility.

Tuberculosis infections are the most common opportunistic infection in rheumatoid arthritis patients treated with tofacitinib.

Anti-CarP antibodies associated with increased disability and higher disease activity in patients with inflammatory polyarthritis.